ArticleChemical science2026
Bioinspired peptide cyclisation enables exploration of cytochrome P450 catalysed sequential oxidation in rufomycin biosynthesis.
Article in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Natural product biosynthetic cytochrome P450s (CYPs) are of increasing interest for their incredible ability to selectively activate inert C-H bonds on highly complex substrates. However, these enzymes are understudied due to difficulties accessing substrates. Here, we use our recently developed peptide cyclisation chemistry to produce a library of natural product peptide analogues to study the rufomycin tailoring CYP, RufM. Rufomycins are antimicrobial non-ribosomal cyclic peptides that undergo sequential alkyl oxidation catalysed by RufM. This transformation is essential for rufomycin antimycobacterial activity but results in several naturally produced derivatives, of which one intermediate has the greatest activity. Due to current interest in engineering the rufomycin pathway to generate derivatives for improved properties, we use our peptide library to explore the complex interplay of enzyme catalysed and spontaneous transformations involved in RufM oxidation, suprising RufM substrate promiscuity and the role of a mechanistically important residue in sequential oxidation. Our work demonstrates the power of our chemistry both as a tool to study biosynthetic tailoring CYPs as potential late-stage functionalizing biocatalysts and to enable antibiotic development.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.